Website: N/A
Stock Symbol: NASDAQ: ACHN
Market Value: N/A (in millions)
We are a biopharmaceutical company focused on the discovery, development and
commercialization of innovative treatments for infectious diseases. Within the
anti-infective market, we are currently concentrating on the development of
antivirals for the treatment of HIV infection and chronic hepatitis C and the
development of antibacterials for the treatment of serious hospital-based
bacterial infections. We have advanced our lead drug candidate, elvucitabine for
the treatment of HIV infection, into phase II clinical trials. In addition, we
are advancing two late-stage preclinical candidates: ACH-1095, an NS4A
antagonist for the treatment of chronic hepatitis C, being developed in
collaboration with Gilead Sciences, and ACH-702 for the treatment of serious
hospital-based bacterial infections. We are also developing a series of
inhibitors of HCV protease in early preclinical assessment.